This Article Full Text Full Text (PDF) All Versions of this Article: 37/8/2153    most recent 01.STR.0000231683.43347.ecv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cox, D. Articles by Fitzgerald, D. J. Search for Related Content PubMed PubMed Citation Articles by Cox, D. Articles by Fitzgerald, D. J. Related Collections Antiplatelets Cardiovascular Pharmacology Platelet function inhibitors Platelets

(Stroke. 2006;37:2153.)
© 2006 American Heart Association, Inc.

Original Contributions

Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers

Dermot Cox, BSc, PhD; Andrew O. Maree, MSc, MD; Michelle Dooley, BSc; Ronán Conroy, BA, Mus B, DSc; Michael F. Byrne, MD Desmond J. Fitzgerald, MD

From the Department of Clinical Pharmacology (D.C., A.O.M., M.D., M.F.B., D.J.F.), Royal College of Surgeons, Dublin, Ireland; the School of Pharmacy (D.C.), Royal College of Surgeons, Dublin, Ireland; and the Department of Epidemiology (R.C.), Royal College of Surgeons, Dublin, Ireland.

Correspondence to Dermot Cox, Department of Clinical Pharmacology, Royal College of Surgeons, 123 St Stephens Green, Dublin 2, Ireland. E-mail dcox{at}rcsi.ie

Background and Purpose— Aspirin resistance may be relatively common and associated with adverse outcome. Meta-analysis has clearly shown that 75 mg plain aspirin is the lowest effective dose; however, it is not known whether the recent increased use of enteric-coated aspirin could account for aspirin resistance. This study was designed to determine whether enteric-coated aspirin is as effective as plain aspirin in healthy volunteers.

Methods— Seventy-one healthy volunteers were enrolled in 3 separate bioequivalence studies. Using a crossover design, each volunteer took 2 different aspirin preparations. Five aspirin preparations were evaluated, 3 different enteric-coated 75-mg aspirins, dispersible aspirin 75 mg and asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily). Serum thromboxane (TX) B₂ levels and arachidonic acid–induced platelet aggregation were measured before and after 14 days of treatment.

Results— All other aspirin preparations tested were inferior to dispersible aspirin (P<0.001) in their effect on serum TXB₂ level. Treatment failure (<95% inhibition serum TXB₂ formation) occurred in 14 subjects, none of whom were taking dispersible aspirin. Mean weight for those demonstrating treatment failure was greater than those with complete TXB₂ (>99%) inhibition (P<0.001). Using logistic regression analysis an 80-kg subject had a 20% probability of treatment failure. Asasantin was the most potent preparation in terms of inhibition of platelet aggregation.

Conclusions— Equivalent doses of the enteric-coated aspirin were not as effective as plain aspirin. Lower bioavailability of these preparations and poor absorption from the higher pH environment of the small intestine may result in inadequate platelet inhibition, particularly in heavier subjects.

Key Words: antiplatelet drugs • aspirin • cyclooxygenase • platelet inhibitors

This article has been cited by other articles:

				C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]

				R. F. Storey Variability of response to antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A21 - A27. [Abstract] [Full Text] [PDF]

				M. Fisher and T. Johns Letter by Fisher and Johns Regarding Article, "Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease" Circulation, November 6, 2007; 116(19): e521 - e521. [Full Text] [PDF]

				C. L. Campbell, S. Smyth, G. Montalescot, and S. R. Steinhubl Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review JAMA, May 9, 2007; 297(18): 2018 - 2024. [Abstract] [Full Text] [PDF]

				A. O. Maree and D. J. Fitzgerald Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease Circulation, April 24, 2007; 115(16): 2196 - 2207. [Full Text] [PDF]

				D. J. Fitzgerald and A. Maree Aspirin and Clopidogrel Resistance Hematology, January 1, 2007; 2007(1): 114 - 120. [Abstract] [Full Text] [PDF]

				Antiplatelet Activity with Low-Dose, Enteric-Coated Aspirin Journal Watch Cardiology, August 23, 2006; 2006(823): 5 - 5. [Full Text]